AIR Option 1: Technology Translation: Glycan based point-of-care diagnostics

这个PFI：空气技术翻译项目专注于翻译糖科学的基础研究，以填补传染病病原体快速检测试剂盒领域的技术空白。翻译的科学具有以下独特的特点：小分子是敏感的、选择性的和坚固的，易于大量生产而不会出现批次到批次的变化，易于与不同的传感器表面结合，可以直接用作生物传感应用中的识别分子，或者可以与现有技术结合使用。这些功能提供了快速检测试剂盒，无需冷藏即可延长保质期，因此可以在包括低资源地区在内的各种环境中使用，可以由未经培训的人员使用，而且与该市场领域领先的基于抗体或核酸的竞争技术相比，价格低廉。该项目通过在快速诊断测试中开发和整合糖共轭化合物来实现其目标，从而为选定的感染性病原体产生一个概念验证原型。该伙伴关系让工业合作伙伴在生物传感器市场提供指导，因为合作伙伴积极参与快速诊断的研究和开发以及其他开发方面，如优化、测试、产品定位等，因为这些方面涉及将科学/技术转化为可能导致竞争性商业现实的道路的潜力。该项目的潜在经济影响预计将在未来五到六年内非常显著，因为护理点诊断的市场估计超过200亿美元。这项新技术可以克服目前快速检测试剂盒存在的一些问题，这将有助于美国在这一市场领域的竞争力。从长远来看，社会影响将是降低发病率和死亡率，因为早期诊断是选择适当对策以控制和尽量减少有害毒素和病原体影响的关键。

This PFI: AIR Technology Translation project focuses on translating basic research in glycoscience to fill a technology gap in the field of rapid detection kits for infectious agents. The translated science has the following unique features: The small molecules are sensitive, selective, and robust, easy to produce in large quantities with no lot-to-lot variation, easy conjugation to different sensor surfaces, can be used directly as recognition molecules in bio-sensing applications or can be used in combination with existing technologies. These features provide rapid test kits that will have extended shelf life without the requirement of refrigeration and therefore can be used in a variety of settings including low resource areas, can be used by untrained personnel, and are inexpensive when compared to the leading competing antibody or nucleic acid based technology in this market space. The project accomplishes its objectives by developing and integrating glycoconjugates in a rapid diagnostic test resulting in a proof-of-concept prototype for select infectious agents. The partnership engages industrial partners to provide guidance in the biosensor marketplace as the partners are actively involved in the research and development of rapid diagnostics and other development aspects such as optimization, testing, product positioning, etc. as they pertain to the potential to translate the science/technology along a path that may result in a competitive commercial reality. The potential economic impact of this project is expected to be very significant in the next five to six years as the market for point of care diagnostics is estimated to be over twenty billion dollars. This novel technology can overcome some of the problems associated with current rapid test kits, which will contribute to the U.S. competitiveness in this market space. The societal impact, long term, will be decreased morbidity and mortality as early diagnosis is key to selecting appropriate countermeasures to control and minimize the impact of harmful toxins and pathogens.